For the quarter ended September 2025, ResMed (RMD) reported revenue of $1.34 billion, up 9.1% over the same period last year. EPS came in at $2.55, compared to $2.20 in the year-ago quarter.
The reported revenue represents a surprise of +0.94% over the Zacks Consensus Estimate of $1.32 billion. With the consensus EPS estimate being $2.49, the EPS surprise was +2.41%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- U.S., Canada, and Latin America- Devices: $413.4 million versus $409.2 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change.
- U.S., Canada, and Latin America- Masks and other: $361.3 million compared to the $355.76 million average estimate based on four analysts. The reported number represents a change of +11.9% year over year.
- Combined Europe, Asia, and other markets- Total: $394.7 million versus $385.76 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
- Combined Europe, Asia, and other markets- Devices: $266.9 million versus the four-analyst average estimate of $257.17 million. The reported number represents a year-over-year change of +10.6%.
- Combined Europe, Asia, and other markets- Masks and other: $127.8 million compared to the $128.59 million average estimate based on four analysts. The reported number represents a change of +7.2% year over year.
- U.S., Canada, and Latin America- Total: $774.8 million versus $764.96 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
- Global revenue- Total Sleep and Breathing Health: $1.17 billion compared to the $1.15 billion average estimate based on five analysts. The reported number represents a change of +9.5% year over year.
- Global revenue- Residential Care Software: $166.1 million versus $170.38 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change.
- Global revenue- Total Devices: $680.3 million versus the four-analyst average estimate of $666.36 million. The reported number represents a year-over-year change of +8.7%.
- Global revenue- Total Masks and other: $489.1 million versus the four-analyst average estimate of $484.35 million. The reported number represents a year-over-year change of +10.7%.
View all Key Company Metrics for ResMed here>>>
Shares of ResMed have returned -6.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ResMed Inc. (RMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
